Remap Consulting recent analysis: “Are Payers Adapting Biosimilar Pricing and Reimbursement Approval Pathways to Optimize Healthcare Savings?” was presented at ISPOR’s 20th Annual International Meeting in Philadelphia.
From the 12 markets investigated, only 2 markets (Belgium and Switzerland) have dedicated biosimilar pathways. The remaining markets either require biosimilars to go through the standard P&R pathways (5 markets) or via an abbreviated process (5 markets, similar to a generic P&R pathway).
The implication is that European payers have yet to consider biosimilars to be clinically comparable to their reference products or to fully recognize the potential healthcare savings from having an expedited biosimilar P&R approval process.
The full analysis can be found here: EU payer P&R process for biosimilars 2015 ISPOR Poster v1_0